Search results for " Kidney disease"

showing 10 items of 160 documents

Oxidative Stress in Non-Dialysis-Dependent Chronic Kidney Disease Patients

2021

Background: Cardiovascular complications are the leading cause of morbidity and mortality at any stage of chronic kidney disease (CKD). Moreover, the high rate of cardiovascular mortality observed in these patients is associated with an accelerated atherosclerosis process that likely starts at the early stages of CKD. Thus, traditional and non-traditional or uremic-related factors represent a link between CKD and cardiovascular risk. Among non-conventional risk factors, particular focus has been placed on anaemia, mineral and bone disorders, inflammation, malnutrition and oxidative stress and, in this regard, connections have been reported between oxidative stress and cardiovascular disease…

0301 basic medicinemedicine.medical_specialtyAntioxidantHealth Toxicology and Mutagenesismedicine.medical_treatment030232 urology & nephrologyRenal functionInflammationOxidative phosphorylationmedicine.disease_causeArticle03 medical and health scienceschemistry.chemical_compound0302 clinical medicinecardiovascular diseaseMalondialdehydeInternal medicineHumansMedicineoxidative stressRenal Insufficiency Chronicbusiness.industryPublic Health Environmental and Occupational HealthRGlutathionemedicine.diseaseMalondialdehyde030104 developmental biologyEndocrinologychemistry8-Hydroxy-2'-DeoxyguanosineChronic DiseaseMedicinemedicine.symptombusinessOxidation-ReductionOxidative stresschronic kidney diseaseKidney diseaseInternational Journal of Environmental Research and Public Health
researchProduct

Aggravated Atherosclerosis and Vascular Inflammation With Reduced Kidney Function Depend on Interleukin-17 Receptor A and Are Normalized by Inhibitio…

2018

Visual Abstract

0301 basic medicinemedicine.medical_specialtylcsh:Diseases of the circulatory (Cardiovascular) systemIl17ra interleukin-17 receptor A (gene name)medicine.medical_treatmentInterleukin-17 receptormacrophage030204 cardiovascular system & hematologyLesionPRECLINICAL RESEARCH03 medical and health sciencesPCR polymerase chain reaction0302 clinical medicineInternal medicinemedicineMacrophageReceptorbusiness.industryCKD chronic kidney diseaseLDLr low-density lipoprotein receptorIL interleukinBlockadeEndothelial stem cell030104 developmental biologyEndocrinologyCytokinelcsh:RC666-701Interleukin 17medicine.symptomatherosclerosisCardiology and Cardiovascular Medicinebusinessinterleukin 17chronic kidney diseaseJACC: Basic to Translational Science
researchProduct

Anticancer Potential of Citrus Juices and Their Extracts: A Systematic Review of Both Preclinical and Clinical Studies

2017

Background: During the last decades, a huge body of evidence has been accumulated suggesting that Citrus fruits and their juices might have a role in preventing many diseases including cancer. Objective: To summarize the numerous evidences on the potential of Citrus juices and their extracts as anticancer agents. Data sources: A systematic review of articles written in English using MEDLINE (1946-present), EMBASE (1974-present) and Web of Sciences (1970-present) was performed independently by two reviewers. Search terms included Citrus, Citrus aurantifolia, Citrus sinensis, Citrus paradisi, Citrus fruits, Citrus fruits extract, cancer, neoplasm, neoplasia, tumor, metastasis, carcinogenesis,…

0301 basic medicineproliferationCitrus aurantifoliaUremic toxinsMEDLINECITRUS JUICEIndoxyl sulfate03 medical and health sciences0302 clinical medicineNeuroinflammationsystematic reviewCitrus paradisiChronic kidney diseaseBotanycancerMedicinePharmacology (medical)NeurodegenerationSystematic reviehumansPharmacologyTraditional medicineIndoxyl sulfate Neuroinflammation Oxidative stress Neurodegeneration Uremic toxins Chronic kidney disease Alternative medicine Cancer Citrus juice Humans In vitro In vivo Proliferation Systematic revie Pharmacology Pharmacology (medical)alternative medicinebusiness.industryData synthesislcsh:RM1-950food and beveragesin vitroin vivolcsh:Therapeutics. Pharmacology030104 developmental biologySystematic reviewSearch termsOxidative stress030220 oncology & carcinogenesisCitrus juicebusinessCitrus × sinensisFrontiers in Pharmacology
researchProduct

HIV infection with viro-immunological dissociation in a patient with polycystic kidney disease: Candidate for transplantation?

2016

Highlights • Autosomal dominant polycystic kidney disease is the most common among inherited cystic kidney diseases. • Patients with HIV infection are at risk of developing acute kidney injury and chronic kidney disease. • We provide the first report of HIV infection in a patient with polycystic kidney disease. • Lymphopenia should not contraindicate kidney transplantation in patients with HIV infection.

030232 urology & nephrologyHuman immunodeficiency virus (HIV)Case ReportViro-immunological dissociationmedicine.disease_causeVirological response03 medical and health sciences0302 clinical medicinePolycystic kidney diseaseLymphopeniaPolycystic kidney diseaseMedicine030212 general & internal medicineStage (cooking)Kidney transplantationTransplantationurogenital systembusiness.industryHIV; Lymphopenia; Polycystic kidney disease; Transplantation; Viro-immunological dissociation; Infectious Diseasesvirus diseasesHIVmedicine.diseaseAntiretroviral therapyTransplantationInfectious DiseasesImmunologybusinessIDCases
researchProduct

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care

2018

Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterized by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations. Individuals with ADPKD should have access to lifelong, multidisciplinary, specialist and patient-centred care involving: (i) a holistic and comprehensive assessment of the manifestations, complications, prognosis and impact of the disease (in physical, psychological and social terms) on the patient and their family; (ii) access to treatment to relieve symptoms, manage complications, preserve kidney function, lower the risk of cardiovascular disease and maintain quality of life;…

2747 Transplantation030232 urology & nephrologyAutosomal dominant polycystic kidney diseaseINTRACRANIAL ANEURYSMS610 Medicine & healthBLOOD-PRESSUREDiseaseClinical practiceGUIDELINES10052 Institute of Physiology03 medical and health sciencesAll institutes and research themes of the Radboud University Medical Center0302 clinical medicineQuality of life (healthcare)NursingQUALITY-OF-LIFEPolycystic kidney diseaseMultidisciplinary approachHealth caremedicinePolycystic kidney diseaseCKDMultispecialist care030212 general & internal medicineDisease management (health)ADPKDOUTCOMESTransplantation2727 NephrologyScience & Technologypolycystic kidney diseasebusiness.industryRENAL REPLACEMENT THERAPYPATIENT PERSPECTIVESUrology & Nephrologymedicine.diseasePREVALENCEclinical practiceTransplantationRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]CLINICAL-PRACTICENephrologymultispecialist care570 Life sciences; biologybusinessLife Sciences & Biomedicine
researchProduct

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan : what …

2019

Albuminuria; Atrasentan; Canagliflozin Albuminuria; Atrasentan; Canagliflozina Albuminúria; Atrasentan; Canagliflozina In April 2019, two major Phase 3 randomized clinical trials were published that assessed primary renal outcomes in diabetic kidney disease (DKD) in type 2 diabetes mellitus (T2DM). The Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) tested an already available antidiabetic drug, canagliflozin, and the Study of Diabetic Nephropathy with Atrasentan (SONAR) tested a novel molecule, the endothelin-1 receptor blocker atrasentan, both on top of renin-angiotensin system blockade. Both trials demonstrated significant nephroprot…

:compuestos heterocíclicos::compuestos heterocíclicos de 1 anillo::dioxoles::benzodioxoles::atrasentán [COMPUESTOS QUÍMICOS Y DROGAS]030232 urology & nephrologysodium-glucose cotransporter-2 (SGLT2) inhibitor:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Diabetic nephropathychemistry.chemical_compound0302 clinical medicineChronic kidney diseaseClinical endpointNefropaties diabètiques - Tractament:Other subheadings::/therapeutic use [Other subheadings]canagliflozin:Otros calificadores::Otros calificadores::/tratamiento farmacológico [Otros calificadores]CanagliflozinSglt2 Inhibitors:enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::nefropatías diabéticas [ENFERMEDADES]Sodium-glucose cotransporter-2 (SGLT2) inhibitorNephrologyendothelinmedicine.drugmedicine.medical_specialty:hidratos de carbono::glicósidos::glucósidos::canagliflozina [COMPUESTOS QUÍMICOS Y DROGAS]UrologyRenal functionalbuminuriaEndothelinNephropathy:Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Nephropathies [DISEASES]03 medical and health sciencesmedicineAlbuminuriaPirrolidina - Ús terapèutic:Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Dioxoles::Benzodioxoles::Atrasentan [CHEMICALS AND DRUGS]CanagliflozinDiabetic kidney diseaseTransplantationCreatinine:Carbohydrates::Glycosides::Glucosides::Canagliflozin [CHEMICALS AND DRUGS]atrasentan:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryAtrasentanGlucòsids - Ús terapèuticmedicine.diseasediabetic kidney diseasechemistryAtrasentanbusinesschronic kidney diseaseKidney disease
researchProduct

Adhesion Molecules in Kidney Diseases

2010

Adhesion molecules Kidney diseases Cell-cell adhesion Intracellular signaling cascade
researchProduct

Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection

2019

Background and aims Chronic hepatitis C virus (HCV) infection increases the risk of incident chronic kidney disease (CKD) and progression to end-stage renal disease (ESRD). Previously available direct-acting antiviral regimens are not approved for patients with advanced CKD across all HCV genotypes. Methods EXPEDITION-5 is a phase 3 study to evaluate efficacy and safety of the fixed-dose combination of glecaprevir and pibrentasvir (G/P) for chronic HCV infection (genotype 1 through 6) in adults without cirrhosis or with compensated cirrhosis and with stage 3b, 4 or 5 CKD. Patients received approved duration of G/P according to HCV genotype, cirrhosis status and prior HCV treatment experienc…

AdultCyclopropaneshepatitis C virusmedicine.medical_specialtyAminoisobutyric AcidsPyrrolidinesCirrhosisProlineLactams Macrocyclicmedicine.medical_treatmentAntiviral Agents03 medical and health sciences0302 clinical medicineLeucineQuinoxalinesInternal medicineGenotypeHumansMedicineAdverse effectDialysisSulfonamidesdirect-acting antiviralpangenotypicHepatologychronic kidney disease; cirrhosis; direct-acting antiviral; hepatitis C virus; pangenotypicbusiness.industrycirrhosisGlecaprevirHepatitis C Chronicmedicine.diseasePibrentasvirDrug Combinations030220 oncology & carcinogenesisBronchitisBenzimidazoles030211 gastroenterology & hepatologybusinesschronic kidney diseaseKidney disease
researchProduct

Microproteinuria as an index of initial renal lesion in patients with rheumatoid arthritis.

1990

Our investigation included 20 patients with rheumatoid arthritis and a negative routine (albustix) proteinuria test, and 20 healthy controls. The albustix test was compared with a method based on multifractional Cellogel RS electrophoresis of urinary proteins. The albustix test was found to be not reliable in patients with RA. Microproteinuria was in fact detected by the electrophoresis method in 12 out of 20 RA patients. Eleven patients showed glomerular type proteinuria (which was "selective" in 5 patients and "non-selective" in 6 patients), and 1 patient showed mixed type proteinuria. Electrophoresis failed to show microproteinuria in the controls. The high sensitivity, easy handling and…

AdultElectrophoresisMaleSettore MED/14 - NefrologiaSettore MED/09 - Medicina InternaMiddle AgedAdult Aged Arthritis Rheumatoid/complications Arthritis Rheumatoid/urine* Electrophoresis/methods Female Humans Kidney Diseases/etiology Kidney Diseases/urine* Male Middle Aged Proteinuria/etiology Proteinuria/urine*Settore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheArthritis RheumatoidProteinuriaSettore MED/16 - ReumatologiaHumansFemaleKidney DiseasesAged
researchProduct

A constitutive BCL2 down-regulation aggravates the phenotype of PKD1-mutant-induced polycystic kidney disease

2017

IF 5.340; International audience; The main identified function of BCL2 protein is to prevent cell death by apoptosis. Mice knock-out for Bcl2 demonstrate growth retardation, severe polycystic kidney disease (PKD), gray hair and lymphopenia, and die prematurely after birth. Here, we report a 40-year-old male referred to for abdominal and thoracic aortic dissection with associated aortic root aneurysm, PKD, lymphocytopenia with a history of T cell lymphoblastic lymphoma, white hair since the age of 20, and learning difficulties. PKD, which was also detected in the father and sister, was related to an inherited PKD1 mutation. The combination of PKD with gray hair and lymphocytopenia was also r…

AdultMale0301 basic medicineTRPP Cation Channelsphenotypebcl2 geneBiologymicro rnaMice03 medical and health sciencesdown-regulationsymptom aggravating factorshemic and lymphatic diseasest-lymphocyteGene expressionGeneticsmedicinePolycystic kidney diseaseAnimalsHumansGenetic Predisposition to Disease[ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human geneticsgenesMolecular BiologyGeneGenetics (clinical)Exome sequencingMice KnockoutPKD1apoptosisExonsGeneral MedicinePolycystic Kidney Autosomal Dominantmedicine.diseasePhenotypePedigreeUp-Regulation3. Good healthMicroRNAs030104 developmental biologyMRNA SequencingProto-Oncogene Proteins c-bcl-2[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsImmunologyCancer researchLymphocytopeniapolycystic kidney diseasesbcl-2 proteinHuman Molecular Genetics
researchProduct